2019冠状病毒病（COVID-19）大流行重新激发了单克隆抗体治疗传染病的兴趣。在过去的20年里，累积了实验数据显示放射免疫疗法（RIT）在治疗传染病方面的潜力。此外，COVID-19大流行在严重免疫抑制的后COVID-19患者中引发了机会性真菌感染的新景观。我们分析了针对小鼠模型和健康犬共享的“泛抗原”的真菌病原体的靶向治疗近期研究结果；以及发展假体关节感染（PJI）的RIT；研究RIT作为潜在的人类免疫缺陷病毒（HIV）治愈策略以及其机制和安全性。文献综述使用PubMed和Google Scholar进行，并包括2000年至2022年的相关文章。在临床前开发后，一些感染性疾病的RIT应用可以提早进入诊所：（1）机会性真菌感染的RIT可能有助于拯救生命，因为目前的抗真菌药物在严重免疫受损患者中不起作用；（2）PJI患者的RIT。在这些患者中成功应用RIT将有助于将RIT的应用扩展到其他类似易感人群，如免疫系统受损的癌症患者和器官移植接受者。

Corona Virus Disease of 2019 (COVID-19) pandemic has renewed interest in monoclonal antibodies for treating infectious diseases. During last two decades experimental data has been accumulated showing the potential of radioimmunotherapy (RIT) of infectious diseases. In addition, COVID-19 pandemic has created a novel landscape for opportunistic fungal infections in post-COVID-19 patients resulting from severe immune suppression.We analyze recent results on targeting "pan-antigens" shared by fungal pathogens in mouse models and in healthy dogs; on developing RIT of prosthetic joint infections (PJI); examine RIT as potential human immunodeficiency virus (HIV) cure strategy and analyze its mechanisms and safety. Literature review was performed using PubMed and Google Scholar and includes relevant articles from 2000 to 2022.Some of the RIT of infection applications can, hopefully, be moved into the clinic earlier than others after preclinical development: (1) RIT of opportunistic fungal infections might contribute to saving lives as current antifungal drugs do not work in severely immunocompromised patients; (2) RIT of patients with PJI. Success of RIT in these patients will allow to expand the application of RIT to other similarly vulnerable patients' populations such as cancer patients with weakened immune system and organ transplant recipients.